27475-09-8

Usage

Uses

Used in Fragrance Industry:
2-Benzyl-5-acetyl methyl salicylate is used as a fragrance ingredient for its ability to impart a pleasant, sweet, and slightly floral scent to perfumes, soaps, lotions, and other personal care products. Its unique aroma profile contributes to the complexity and appeal of various fragrance compositions.
Used in Cosmetic Industry:
In the cosmetic industry, 2-Benzyl-5-acetyl methyl salicylate serves as a key component in the formulation of creams, lotions, and other skincare products. Its addition enhances the sensory experience by providing a pleasant scent, which can improve consumer acceptance and enjoyment of the products.
Used in Food Industry:
As a flavoring agent, 2-Benzyl-5-acetyl methyl salicylate is utilized in the food industry to add depth and complexity to the taste profiles of various food products. Its sweet and slightly floral notes can complement and enhance the flavors of confectionery, beverages, and other edible items.
Used in Pharmaceutical Industry:
2-Benzyl-5-acetyl methyl salicylate is used as an active ingredient in topical pain relief products due to its anti-inflammatory and analgesic properties. Its incorporation into creams, ointments, and gels can provide targeted relief for muscle aches, joint pain, and other inflammatory conditions.
Used in Research and Development:
In the field of research and development, 2-Benzyl-5-acetyl methyl salicylate is studied for its potential applications in new product formulations and for understanding its mechanisms of action. This includes exploring its potential synergistic effects with other ingredients and its role in modulating biological responses.

InChI:InChI=1/C17H16O4/c1-12(18)14-8-9-16(15(10-14)17(19)20-2)21-11-13-6-4-3-5-7-13/h3-10H,11H2,1-2H3

Synthetic route

estere metilico dell'acido 5-acetilsalicilico (16475-90-4) + benzyl bromide (100-39-0) → 5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8)

Conditions	Yield
With potassium carbonate In acetonitrile at 85℃; for 9h;	100%
With potassium carbonate In acetonitrile at 75℃; for 16h;	100%
With potassium carbonate In acetonitrile for 24h;	96.6%

benzyl bromide (100-39-0) → 5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8)

Conditions	Yield
Stage #1: estere metilico dell'acido 5-acetilsalicilico With potassium carbonate In acetonitrile for 0.166667h; Stage #2: benzyl bromide In methanol at 85℃; for 9.25h;	100%

estere metilico dell'acido 5-acetilsalicilico (16475-90-4) + benzyl chloride (100-44-7) → 5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8)

Conditions	Yield
With potassium carbonate; potassium iodide In N,N-dimethyl-formamide at 50 - 65℃; for 2h;	98.5%
With sodium carbonate In N,N-dimethyl-formamide at 110 - 115℃; for 2h;	84.7%
With sodium In ethanol for 30h; Heating;	55%
With sodium carbonate; sodium iodide In acetonitrile for 16h; Heating / reflux;	55%
With potassium carbonate

estere metilico dell'acido 5-acetilsalicilico (16475-90-4) + benzyl bromide (100-39-0) + butanone (78-93-3) → 5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8)

Conditions	Yield
With hydrogenchloride; potassium carbonate	71.4%

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 2-benzyloxy-5-(2-bromoacetyl)benzoic acid methyl ester (27475-14-5)

Conditions	Yield
With bromine In chloroform at 0 - 20℃; Inert atmosphere;	97%
With N-Bromosuccinimide; sulfuric acid In acetonitrile at 50℃; for 1h;	81%
With aluminium trichloride; bromine In diethyl ether for 3h; Ambient temperature;	78%

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 5-acetyl-2-(benzyloxy)benzoic acid (201663-18-5)

Conditions	Yield
With hydrogenchloride; sodium hydroxide In tetrahydrofuran; methanol	91%
Stage #1: 5-acetyl-2-benzyloxybenzoic acid methyl ester With sodium hydroxide; water In tetrahydrofuran; methanol for 8h; Stage #2: With hydrogenchloride In tetrahydrofuran; methanol; water	91%
Stage #1: 5-acetyl-2-benzyloxybenzoic acid methyl ester With sodium hydroxide; water In tetrahydrofuran; methanol for 8h; Stage #2: With hydrogenchloride In tetrahydrofuran; methanol; water	91%

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) + N,N-dimethyl-formamide dimethyl acetal (4637-24-5) → methanol (67-56-1) + methyl 2-(benzyloxy)-5-(3-(dimethylamino)acryloyl)benzoate (1031418-13-9)

Conditions	Yield
In N,N-dimethyl-formamide at 110 - 115℃; for 8h;	A n/a B 82.1%

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 5-(1-amino-ethyl)-2-benzyloxy-benzoic acid methyl ester

Conditions	Yield
With ammonium acetate; sodium cyanoborohydride In methanol

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 2-benzyloxy-5-(1-{2-[3-(4-carbamimidoyl-phenyl)-ureido]-acetylamino}-ethyl)-benzoic acid methyl ester

Conditions	Yield
Multi-step reaction with 2 steps 1: NaCNBH3; NH4OAc / methanol 2: O-[(EtOCO)cyanomethyleneamino]-N,N,N',N'-Me4-uronium*BF4; N-ethylmorpholine / dimethylformamide View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 2-Hydroxymethyl-4-(1-hydroxy-2-pyrrolidin-1-yl-ethyl)-phenol

Conditions	Yield
Multi-step reaction with 4 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 15 h, reflux; 2.) ether, alcohol 3: 44 percent / LiAlH4 / diethyl ether; tetrahydrofuran / 4 h / Heating 4: 68 percent / hydrogen / 10percent Pd/C / 760 Torr / Ambient temperature View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 2-Hydroxymethyl-4-[1-hydroxy-2-(4-methyl-piperazin-1-yl)-ethyl]-phenol

Conditions	Yield
Multi-step reaction with 4 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 15 h, reflux; 2.) ether, alcohol 3: 41 percent / LiAlH4 / diethyl ether; tetrahydrofuran / 4 h / Heating 4: 34 percent / hydrogen / 10percent Pd/C / 760 Torr / Ambient temperature View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 2-Hydroxymethyl-4-[1-hydroxy-2-(4-phenyl-piperidin-1-yl)-ethyl]-phenol

Conditions	Yield
Multi-step reaction with 4 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 15 h, reflux; 2.) ether, alcohol 3: 41 percent / LiAlH4 / diethyl ether; tetrahydrofuran / 4 h / Heating 4: 58 percent / hydrogen / 10percent Pd/C / 760 Torr / Ambient temperature View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 2-Hydroxymethyl-4-{1-hydroxy-2-[(4-phenyl-cyclohexylmethyl)-amino]-ethyl}-phenol

Conditions	Yield
Multi-step reaction with 4 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 24 h, reflux; 2.) ether, alcohol 3: 71 percent / LiAlH4 / diethyl ether; tetrahydrofuran / 4 h / Heating 4: 59 percent / hydrogen / 10percent Pd/C / 760 Torr / Ambient temperature View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 1-(4-Benzyloxy-3-hydroxymethyl-phenyl)-2-pyrrolidin-1-yl-ethanol (74068-64-7)

Conditions	Yield
Multi-step reaction with 3 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 15 h, reflux; 2.) ether, alcohol 3: 44 percent / LiAlH4 / diethyl ether; tetrahydrofuran / 4 h / Heating View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 4-{2-[1-(4-Cyclohexyl-phenyl)-ethylamino]-1-hydroxy-ethyl}-2-hydroxymethyl-phenol

Conditions	Yield
Multi-step reaction with 4 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 74 percent / 24 h / Heating 3: LiAlH4 / diethyl ether; tetrahydrofuran / 4 h / Heating 4: 42 percent / hydrogen / 10percent Pd/C / 3040 Torr / Ambient temperature View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 4-{2-[2-(4-Cyclohexyl-phenyl)-1-methyl-ethylamino]-1-hydroxy-ethyl}-2-hydroxymethyl-phenol

Conditions	Yield
Multi-step reaction with 4 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 24 h, reflux; 2.) ether, alcohol 3: LiAlH4 / diethyl ether; tetrahydrofuran / 4 h / Heating 4: 21 percent / hydrogen / 10percent Pd/C / 3040 Torr / Ambient temperature View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 1-(4-Benzyloxy-3-hydroxymethyl-phenyl)-2-(4-phenyl-piperidin-1-yl)-ethanol (74068-68-1)

Conditions	Yield
Multi-step reaction with 3 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 15 h, reflux; 2.) ether, alcohol 3: 41 percent / LiAlH4 / diethyl ether; tetrahydrofuran / 4 h / Heating View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 2-Hydroxymethyl-4-(1-hydroxy-2-piperidin-1-yl-ethyl)-phenol; hydrochloride

Conditions	Yield
Multi-step reaction with 4 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 15 h, reflux; 2.) ether, alcohol 3: 55 percent / LiAlH4 / diethyl ether; tetrahydrofuran / 4 h / Heating 4: 52 percent / hydrogen / 10percent Pd/C / 760 Torr / Ambient temperature View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 2-{Benzyl-[2-(4-cyclohexyl-phenyl)-1-methyl-ethyl]-amino}-1-(4-benzyloxy-3-hydroxymethyl-phenyl)-ethanol (74068-82-9)

Conditions	Yield
Multi-step reaction with 3 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 24 h, reflux; 2.) ether, alcohol 3: LiAlH4 / diethyl ether; tetrahydrofuran / 4 h / Heating View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 1-(4-Benzyloxy-3-hydroxymethyl-phenyl)-2-[benzyl-(4-phenyl-cyclohexylmethyl)-amino]-ethanol (74068-77-2)

Conditions	Yield
Multi-step reaction with 3 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 24 h, reflux; 2.) ether, alcohol 3: 71 percent / LiAlH4 / diethyl ether; tetrahydrofuran / 4 h / Heating View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 2-{Benzyl-[1-(4-cyclohexyl-phenyl)-ethyl]-amino}-1-(4-benzyloxy-3-hydroxymethyl-phenyl)-ethanol (74083-47-9)

Conditions	Yield
Multi-step reaction with 3 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 74 percent / 24 h / Heating 3: LiAlH4 / diethyl ether; tetrahydrofuran / 4 h / Heating View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 5-(2-{Benzyl-[1-(4-cyclohexyl-phenyl)-ethyl]-amino}-acetyl)-2-benzyloxy-benzoic acid methyl ester (74068-80-7)

Conditions	Yield
Multi-step reaction with 2 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 74 percent / 24 h / Heating View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 2-Benzyloxy-5-(2-pyrrolidin-1-yl-acetyl)-benzoic acid methyl ester; hydrochloride

Conditions	Yield
Multi-step reaction with 2 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 15 h, reflux; 2.) ether, alcohol View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 1-(4-Benzyloxy-3-hydroxymethyl-phenyl)-2-piperidin-1-yl-ethanol; hydrochloride

Conditions	Yield
Multi-step reaction with 3 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 15 h, reflux; 2.) ether, alcohol 3: 55 percent / LiAlH4 / diethyl ether; tetrahydrofuran / 4 h / Heating View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 2-Benzyloxy-5-(2-piperidin-1-yl-acetyl)-benzoic acid methyl ester; hydrochloride

Conditions	Yield
Multi-step reaction with 2 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 15 h, reflux; 2.) ether, alcohol View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 1-(4-Benzyloxy-3-hydroxymethyl-phenyl)-2-morpholin-4-yl-ethanol; hydrochloride

Conditions	Yield
Multi-step reaction with 3 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 15 h, reflux; 2.) ether, alcohol 3: 70 percent / LiAlH4 / diethyl ether; tetrahydrofuran / 4 h / Heating View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 2-Benzyloxy-5-(2-morpholin-4-yl-acetyl)-benzoic acid methyl ester; hydrochloride

Conditions	Yield
Multi-step reaction with 2 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 15 h, reflux; 2.) ether, alcohol View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 2-Benzyloxy-5-[2-(4-methyl-piperazin-1-yl)-acetyl]-benzoic acid methyl ester; hydrochloride

Conditions	Yield
Multi-step reaction with 2 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 15 h, reflux; 2.) ether, alcohol View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 2-Benzyloxy-5-[2-(4-phenyl-piperidin-1-yl)-acetyl]-benzoic acid methyl ester; hydrochloride

Conditions	Yield
Multi-step reaction with 2 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 15 h, reflux; 2.) ether, alcohol View Scheme

5-acetyl-2-benzyloxybenzoic acid methyl ester (27475-09-8) → 5-(2-{Benzyl-[2-(4-cyclohexyl-phenyl)-1-methyl-ethyl]-amino}-acetyl)-2-benzyloxy-benzoic acid methyl ester; hydrochloride

Conditions	Yield
Multi-step reaction with 2 steps 1: 78 percent / AlCl3, bromine / diethyl ether / 3 h / Ambient temperature 2: 2.) HCl / 1.) 24 h, reflux; 2.) ether, alcohol View Scheme

Upstream product

• 16475-90-4 estere metilico dell'acido 5-acetilsalicilico 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 78-93-3 butanone 

Downstream Products

• 27475-14-5 2-benzyloxy-5-(2-bromoacetyl)benzoic acid methyl ester 
• 753386-64-0 5-(2-((N-Benzyl-N-isopropyl)-amino-1-hydroxyethyl)-2-benzyloxybenzoesaeure-methylester 
• 744137-94-8 5-(N-Benzyl-N-isopropylglycyl)-2-benzyloxy-benzoesaeure-methylester 
• 24085-69-6 4-Benzyloxy-α¹-(N-benzyl-N-isopropylamino)-methyl-α³-dimethyl-m-xylol-α¹,α³-diol 
• 201663-18-5 5-acetyl-2-(benzyloxy)benzoic acid 
• 63416-79-5 5-(Dichloroacetyl)-2-(phenylmethoxy)benzoic acid, methyl ester 
• 63416-80-8 C₁₇H₁₄O₅ 
• 135271-49-7 salmeterol xinafoate 
• 89365-50-4 salmeterol 
• 1351281-52-1 methyl 5-(2-(benzyl(6-(4-phenylbutoxy)hexyl)amino)acetyl)-2-(benzyloxy)benzoate 
• 943969-38-8 2-(benzyl-(6-(4-phenylbutoxy)hexyl)amino)-1-(4-(benzyloxy)-3-(hydroxymethyl)phenyl)ethanol 
• 324000-05-7 2-tert-butylamino-1-(4-hydroxy-2-hydroxymethyl-phenyl)ethanol 
• 174607-70-6 methyl 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2-(benzyloxy) benzoate 
• 56796-66-8 α¹-[[(1,1-dimethylethyl)amino]methyl]-4-(benzyloxy)-1,3-benzenedimethanol 

Relevant academic research and scientific papers

A chromatography-free synthesis of racemic salbutamol hemisulfate

Our efforts to achieve an efficient synthesis of racemic salbutamol hemisulfate are described. The selected chemical route starts from commodity chemicals and allows the generation of salbutamol hemisulfate in 5 steps and 44% overall yield without any purification by column chromatography. The reaction sequence has been optimized to provide the title compound using robust procedures. Emphasis on reproducibility and experimental simplicity drove the work described herein.

Conformational control enabled by the fluorine gauche effect in a model of the β2-AR agonist salbutamol (Ventolin)

The bronchodilator salbutamol adopts a characteristic gauche conformation about the ?O-C-C-N torsion angle. This topology is predicated on stabilizing stereoelectronic interactions of the type σ → σC-X*. X-ray crystallographic analysis of salbutamol also indicates that an intramolecular hydrogen bond reinforces this intuitive conformation (?O-C-C-N ≈ 60°). In this study, we demonstrate that single site OH → F substitution in model salbutamol systems preserves the gauche conformational preference by virtue of reinforcing hyperconjugative interactions of the type σC-H → σC-F* and σC-C → σC-N*. Since the amine remains fully protected throughout this conformational analysis, intramolecular hydrogen bonding can be discounted. Conformational mimesis is confirmed by NMR spectroscopy in solution, and also in the solid state.

PROCESS FOR THE PREPARATION OF SALMETEROL AND ITS INTERMEDIATES

The present invention discloses a process for the preparation of methyl 2-(benzyloxy)- 5-(2-bromoacetyl)benzoate (V), comprising: (d) benzylating methyl-5-acetyl-2-hydroxybenzoate (VIII) with benzyl chloride in the presence of a base and a catalyst in a suitable polar solvent to obtain 5-acetyl-2- benzyloxy benzoate (VII); (e) brominating methyl 5-acetyl-2-(benzyloxy)benzoate (VII) with a suitable brominating agent in one or more suitable' solvents in the presence of an acid catalyst to obtain methyl 2-(benzyloxy)-5-(2-bromoacetyl)benzoate V; (c) optionally, purifying the methyl 2-(benzyloxy)-5-(2-bromoacetyl)benzoate (V) in a suitable solvent; and (f) isolating the methyl 2-(benzyloxy)-5-(2-bromoacetyl)benzoate (V).

A multivalent approach to the discovery of long-acting β2- adrenoceptor agonists for the treatment of asthma and COPD

A multivalent approach was applied to the design of long-acting inhaled β2-adrenoceptor agonists. A series of dimeric arylethanolamines based on the short acting β2-adrenoceptor agonist albuterol were prepared, varying the nature and length of the linker between the basic nitrogens. None of the C2-symmetric dimers demonstrated increased potency, however dimer 5j, derived from 4-phenethylamine, was found to have increased binding potency in vitro relative to the parent monomer. Optimization of this structure led to the identification of 22 (milveterol) which demonstrates high potency in vitro and long duration of action in a guinea pig model of bronchoprotection.

SPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS

The invention provides compounds of Formula (1) or a pharmaceutically acceptable salt of said compound, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating mammals suffering from the condition of being overweight.

PHENYL SUBSTITUTED PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS POSSESSING BETA AGONIST ACTIVITY

The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.

Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

The invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7a, R7b, W, G1, G2, a, b, c, d and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

NF-KB ACTIVATION INHIBITORS

A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to ―CONH― group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ― CONH―E wherein E has the same meaning as that defined above.

THERAPEUTIC AGENT FOR CANCER

A medicament for the prevention and/or treatment of cancers and the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1? a fused polycyclic heteroaryl group wherein the ring which binds directly to ―CONH― group in the formula (I) is a benzene ring, 2? unsubstituted thiazol-2-yl group, or 3? unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ―CONH―E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula ―O―A wherein A has the same meaning as that defined above and the group represented by formula ― CONH―E wherein E has the same meaning as that defined above.

REMEDIES FOR NEURODEGENERATIVE DISEASES

A medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Alzheimer's disease or the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is 1○ a fused polycyclic heteroaryl group wherein the ring which binds directly to -CONH- group in the formula (I) is a benzene ring, 2○ unsubstituted thiazol-2-yl group, or 3○ unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula -O-A wherein A has the same meaning as that defined above and the group represented by formula -CONH-E wherein E has the same meaning as that defined above.